From Spend to Substance | Ep. 714

Rethinking R&D Productivity in Biopharma

Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary is as always on Thursday focused on the general market update. For the week XBI was UP +1% and remains red at -8% for the year. This week, we’re diving into the real story behind biotech’s most misunderstood metric: R&D productivity. For years, the industry has poured more mon…